163 related articles for article (PubMed ID: 19539256)
1. A prospective, multicenter, randomized trial to assess efficacy of pioglitazone on in-stent neointimal suppression in type 2 diabetes: POPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study).
Takagi T; Okura H; Kobayashi Y; Kataoka T; Taguchi H; Toda I; Tamita K; Yamamuro A; Sakanoue Y; Ito A; Yanagi S; Shimeno K; Waseda K; Yamasaki M; Fitzgerald PJ; Ikeno F; Honda Y; Yoshiyama M; Yoshikawa J;
JACC Cardiovasc Interv; 2009 Jun; 2(6):524-31. PubMed ID: 19539256
[TBL] [Abstract][Full Text] [Related]
2. Pioglitazone to reduce restenosis after bare-metal stent placement?
Nissen SE
JACC Cardiovasc Interv; 2009 Jun; 2(6):532-3. PubMed ID: 19539257
[No Abstract] [Full Text] [Related]
3. Cellular and molecular changes associated with inhibitory effect of pioglitazone on neointimal growth in patients with type 2 diabetes after zotarolimus-eluting stent implantation.
Hong SJ; Kim ST; Kim TJ; Kim EO; Ahn CM; Park JH; Kim JS; Lee KM; Lim DS
Arterioscler Thromb Vasc Biol; 2010 Dec; 30(12):2655-65. PubMed ID: 21030718
[TBL] [Abstract][Full Text] [Related]
4. Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study.
Takagi T; Yamamuro A; Tamita K; Yamabe K; Katayama M; Mizoguchi S; Ibuki M; Tani T; Tanabe K; Nagai K; Shiratori K; Morioka S; Yoshikawa J
Am Heart J; 2003 Aug; 146(2):E5. PubMed ID: 12891212
[TBL] [Abstract][Full Text] [Related]
5. Comparison of bare metal stent with pioglitazone versus sirolimus-eluting stent for percutaneous coronary intervention in patients with Type 2 diabetes mellitus.
Nishio K; Shigemitsu M; Kodama Y; Konno N; Katagiri T; Kobayashi Y
Cardiovasc Revasc Med; 2009; 10(1):5-11. PubMed ID: 19159848
[TBL] [Abstract][Full Text] [Related]
6. Role of pioglitazone in the prevention of restenosis and need for revascularization after bare-metal stent implantation: a meta-analysis.
Patel D; Walitt B; Lindsay J; Wilensky RL
JACC Cardiovasc Interv; 2011 Mar; 4(3):353-60. PubMed ID: 21435616
[TBL] [Abstract][Full Text] [Related]
7. Effect of Pioglitazone in Preventing In-Stent Restenosis after Percutaneous Coronary Intervention in Patients with Type 2 Diabetes: A Meta-Analysis.
Zhao SJ; Zhong ZS; Qi GX; Shi LY; Chen L; Tian W
PLoS One; 2016; 11(5):e0155273. PubMed ID: 27163676
[TBL] [Abstract][Full Text] [Related]
8. Reduction of neointimal hyperplasia after coronary stenting by pioglitazone in nondiabetic patients with metabolic syndrome.
Katayama T; Ueba H; Tsuboi K; Kubo N; Yasu T; Kuroki M; Saito M; Momomura S; Kawakami M
Am Heart J; 2007 May; 153(5):762.e1-7. PubMed ID: 17452150
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of in-stent restenosis in the APPROACH trial (Assessment on the Prevention of Progression by Rosiglitazone On Atherosclerosis in diabetes patients with Cardiovascular History).
García-García HM; Garg S; Brugaletta S; Morocutti G; Ratner RE; Kolatkar NS; Kravitz BG; Miller DM; Huang C; Nesto RW; Serruys PW;
Int J Cardiovasc Imaging; 2012 Mar; 28(3):455-65. PubMed ID: 21359834
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of pioglitazone in patients with ST elevation myocardial infarction treated with primary stent implantation.
Kaneda H; Shiono T; Miyashita Y; Takahashi S; Taketani Y; Domae H; Matsumi J; Mizuno S; Minami Y; Sugitatsu K; Saito S
Heart; 2009 Jul; 95(13):1079-84. PubMed ID: 19321493
[TBL] [Abstract][Full Text] [Related]
11. A prospective randomised study using optical coherence tomography to assess endothelial coverage and neointimal proliferation at 6-months after implantation of a coronary everolimus-eluting stent compared with a bare metal stent postdilated with a paclitaxel-eluting balloon (OCTOPUS Trial): rationale, design and methods.
Poerner TC; Otto S; Gassdorf J; Janiak F; Danzer C; Ferrari M; Figulla HR
EuroIntervention; 2011 May; 7 Suppl K():K93-9. PubMed ID: 22027737
[TBL] [Abstract][Full Text] [Related]
12. Effects of low dose pioglitazone on restenosis and coronary atherosclerosis in diabetic patients undergoing drug eluting stent implantation.
Lee HW; Lee HC; Kim BW; Yang MJ; Park JS; Oh JH; Choi JH; Cha KS; Hong TJ; Kim SP; Song S; Park JH
Yonsei Med J; 2013 Nov; 54(6):1313-20. PubMed ID: 24142633
[TBL] [Abstract][Full Text] [Related]
13. Thiazolidinedione treatment attenuates diffuse neointimal hyperplasia in restenotic lesions after coronary stent implantation in type 2 diabetic patients: an intravascular ultrasound study.
Takagi T; Yamamuro A; Tamita K; Katayama M; Morioka S
J Cardiol; 2005 Apr; 45(4):139-47. PubMed ID: 15875535
[TBL] [Abstract][Full Text] [Related]
14. Catheter-based delivery of fluid paclitaxel for prevention of restenosis in native coronary artery lesions after stent implantation.
Herdeg C; Göhring-Frischholz K; Haase KK; Geisler T; Zürn C; Hartmann U; Wöhrle J; Nusser T; Dippon J; May AE; Gawaz M
Circ Cardiovasc Interv; 2009 Aug; 2(4):294-301. PubMed ID: 20031731
[TBL] [Abstract][Full Text] [Related]
15. A randomized controlled trial of angiography versus intravascular ultrasound-directed bare-metal coronary stent placement (the AVID Trial).
Russo RJ; Silva PD; Teirstein PS; Attubato MJ; Davidson CJ; DeFranco AC; Fitzgerald PJ; Goldberg SL; Hermiller JB; Leon MB; Ling FS; Lucisano JE; Schatz RA; Wong SC; Weissman NJ; Zientek DM;
Circ Cardiovasc Interv; 2009 Apr; 2(2):113-23. PubMed ID: 20031704
[TBL] [Abstract][Full Text] [Related]
16. Randomized trial of insulin versus usual care in reducing restenosis after coronary intervention in patients with diabetes. the STent Restenosis And Metabolism (STREAM) study.
Natarajan MK; Strauss BH; Rokoss M; Buller CE; Mancini GB; Xie C; Sheth TN; Goodhart D; Cohen EA; Seidelin P; Harper W; Gerstein HC
Cardiovasc Revasc Med; 2012; 13(2):95-100. PubMed ID: 22296781
[TBL] [Abstract][Full Text] [Related]
17. Analysis of left main coronary artery bifurcation lesions treated with biolimus-eluting DEVAX AXXESS plus nitinol self-expanding stent: intravascular ultrasound results of the AXXENT trial.
Hasegawa T; Ako J; Koo BK; Miyazawa A; Sakurai R; Chang H; Dens J; Verheye S; Grube E; Honda Y; Fitzgerald PJ
Catheter Cardiovasc Interv; 2009 Jan; 73(1):34-41. PubMed ID: 19089934
[TBL] [Abstract][Full Text] [Related]
18. INtimal hyPerplasia evAluated by oCT in de novo COROnary lesions treated by drug-eluting balloon and bare-metal stent (IN-PACT CORO): study protocol for a randomized controlled trial.
Burzotta F; Brancati MF; Trani C; Porto I; Tommasino A; De Maria G; Niccoli G; Leone AM; Coluccia V; Schiavoni G; Crea F
Trials; 2012 May; 13():55. PubMed ID: 22559260
[TBL] [Abstract][Full Text] [Related]
19. Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study.
Takagi T; Akasaka T; Yamamuro A; Honda Y; Hozumi T; Morioka S; Yoshida K
J Am Coll Cardiol; 2000 Nov; 36(5):1529-35. PubMed ID: 11079654
[TBL] [Abstract][Full Text] [Related]
20. Neointimal Modification With Scoring Balloon and Efficacy of Drug-Coated Balloon Therapy in Patients With Restenosis in Drug-Eluting Coronary Stents: A Randomized Controlled Trial.
Kufner S; Joner M; Schneider S; Tölg R; Zrenner B; Repp J; Starkmann A; Xhepa E; Ibrahim T; Cassese S; Fusaro M; Ott I; Hengstenberg C; Schunkert H; Abdel-Wahab M; Laugwitz KL; Kastrati A; Byrne RA;
JACC Cardiovasc Interv; 2017 Jul; 10(13):1332-1340. PubMed ID: 28683939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
